Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 12 de 12
Filtrar
1.
Clin Pharmacol Ther ; 110(3): 662-676, 2021 09.
Artigo em Inglês | MEDLINE | ID: mdl-34109627

RESUMO

The Pharmacogene Variation Consortium (PharmVar) catalogues star (*) allele nomenclature for the polymorphic human CYP2C9 gene. Genetic variation within the CYP2C9 gene locus impacts the metabolism or bioactivation of many clinically important drugs, including nonsteroidal anti-inflammatory drugs, phenytoin, antidiabetic agents, and angiotensin receptor blockers. Variable CYP2C9 activity is of particular importance regarding efficacy and safety of warfarin and siponimod as indicated in their package inserts. This GeneFocus provides a comprehensive overview and summary of CYP2C9 and describes how haplotype information catalogued by PharmVar is utilized by the Pharmacogenomics Knowledgebase and the Clinical Pharmacogenetics Implementation Consortium.


Assuntos
Citocromo P-450 CYP2C9/genética , Polimorfismo Genético/genética , Alelos , Haplótipos/genética , Humanos , Bases de Conhecimento , Preparações Farmacêuticas/administração & dosagem , Farmacogenética/métodos
2.
Mov Disord ; 36(8): 1899-1910, 2021 08.
Artigo em Inglês | MEDLINE | ID: mdl-33942911

RESUMO

BACKGROUND: Persistent motor or vocal tic disorder (PMVT) has been hypothesized to be a forme fruste of Tourette syndrome (TS). Although the primary diagnostic criterion for PMVT (presence of motor or vocal tics, but not both) is clear, less is known about its clinical presentation. OBJECTIVE: The goals of this study were to compare the prevalence and number of comorbid psychiatric disorders, tic severity, age at tic onset, and family history for TS and PMVT. METHODS: We analyzed data from two independent cohorts using generalized linear equations and confirmed our findings using meta-analyses, incorporating data from previously published literature. RESULTS: Rates of obsessive-compulsive disorder (OCD) and attention deficit hyperactivity disorder (ADHD) were lower in PMVT than in TS in all analyses. Other psychiatric comorbidities occurred with similar frequencies in PMVT and TS in both cohorts, although meta-analyses suggested lower rates of most psychiatric disorders in PMVT compared with TS. ADHD and OCD increased the odds of comorbid mood, anxiety, substance use, and disruptive behaviors, and accounted for observed differences between PMVT and TS. Age of tic onset was approximately 2 years later, and tic severity was lower in PMVT than in TS. First-degree relatives had elevated rates of TS, PMVT, OCD, and ADHD compared with population prevalences, with rates of TS equal to or greater than PMVT rates. CONCLUSIONS: Our findings support the hypothesis that PMVT and TS occur along a clinical spectrum in which TS is a more severe and PMVT a less severe manifestation of a continuous neurodevelopmental tic spectrum disorder. © 2021 The Authors. Movement Disorders published by Wiley Periodicals LLC on behalf of International Parkinson and Movement Disorder Society.


Assuntos
Transtorno do Deficit de Atenção com Hiperatividade , Transtorno Obsessivo-Compulsivo , Transtornos de Tique , Tiques , Síndrome de Tourette , Transtorno do Deficit de Atenção com Hiperatividade/epidemiologia , Comorbidade , Humanos , Transtorno Obsessivo-Compulsivo/epidemiologia , Transtornos de Tique/epidemiologia , Tiques/epidemiologia , Síndrome de Tourette/epidemiologia
3.
Clin Transl Sci ; 14(2): 589-598, 2021 03.
Artigo em Inglês | MEDLINE | ID: mdl-33166056

RESUMO

Pharmacogenetic (PGx) testing is a tool to identify patients at a higher risk of adverse events or treatment failure. The concern for unwanted side effects can limit medication adherence, particularly in children and adolescents. We conducted a pragmatic study to evaluate the acceptability and feasibility and gather pilot data on the utility of PGx testing in a child and adolescent psychiatry clinic. Both physicians and families participated in the study and answered pre-survey and post-survey questionnaires to examine their attitudes toward PGx testing. Patients were randomized into implementation (N = 25) and control groups (N = 24) and underwent PGx testing at the beginning or end of the study, respectively. Clinical consult notes with genotype-guided recommendations were provided to physicians for their consideration in clinical decisions. Patient-reported symptom severity and antidepressant-related side effects were assessed at baseline and for 12 weeks. Both participating physicians and families agreed that PGx testing is a useful tool to improve medication selection. The time from sample collection to having PGx test results was ~ 10 days and 15 days to having consult notes available, which may have impaired test utility in clinical decision making. There were no differences in any clinical end point between the implementation and control arms; however, there were higher antidepressant side effect scores for CYP2D6 poor and intermediate metabolizers after the eighth week of treatment. Our findings revealed benefits and pitfalls with the use of PGx testing in the real-world clinical setting, which may inform the methodology of a larger trial focused on outcomes.


Assuntos
Antidepressivos/efeitos adversos , Efeitos Colaterais e Reações Adversas Relacionados a Medicamentos/prevenção & controle , Transtornos Mentais/tratamento farmacológico , Testes Farmacogenômicos/estatística & dados numéricos , Medicina de Precisão/métodos , Adolescente , Instituições de Assistência Ambulatorial/estatística & dados numéricos , Criança , Tomada de Decisão Clínica/métodos , Citocromo P-450 CYP2D6/genética , Citocromo P-450 CYP2D6/metabolismo , Efeitos Colaterais e Reações Adversas Relacionados a Medicamentos/genética , Estudos de Viabilidade , Feminino , Humanos , Masculino , Transtornos Mentais/genética , Variantes Farmacogenômicos , Projetos Piloto , Estudos Prospectivos , Índice de Gravidade de Doença , Inquéritos e Questionários/estatística & dados numéricos
4.
Clin Pharmacol Ther ; 109(2): 352-366, 2021 02.
Artigo em Inglês | MEDLINE | ID: mdl-32602114

RESUMO

The Pharmacogene Variation Consortium (PharmVar) catalogues star (*) allele nomenclature for the polymorphic human CYP2C19 gene. CYP2C19 genetic variation impacts the metabolism of many drugs and has been associated with both efficacy and safety issues for several commonly prescribed medications. This GeneFocus provides a comprehensive overview and summary of CYP2C19 and describes how haplotype information catalogued by PharmVar is utilized by the Pharmacogenomics Knowledgebase and the Clinical Pharmacogenetics Implementation Consortium (CPIC).


Assuntos
Citocromo P-450 CYP2C19/genética , Alelos , Variação Genética/genética , Genótipo , Haplótipos/genética , Humanos , Bases de Conhecimento , Farmacogenética/métodos
5.
Pharmacogenomics ; 20(12): 891-902, 2019 08.
Artigo em Inglês | MEDLINE | ID: mdl-31453773

RESUMO

Aim: Perform in silico predictions of functional consequences of CYP2C9 variants identified by next-generation sequencing in Puerto Ricans. Methods: Identified low-frequency CYP2C9 variants (minor allele frequencies <2%) were evaluated using the Combined Annotation-Dependent Depletion (CADD v1.3) tools and molecular modeling/docking analysis to predict impact on CYP2C9 activity. Results:CYP2C9*5,*8,*9,*11,*12,*21 and a novel *61 induce conformational changes that affect the binding site of S-warfarin. Most of these deleterious variants occur at higher frequency among individuals with large African ancestry. Conclusion: The unfavorable distance of S-warfarin from heme group, and low-binding interactions due to these CYP2C9 variants, suggest major complications during warfarin therapy. This study contributes to the field by predicting functional alterations of rare CYP2C9 variants for the first time in Hispanics.


Assuntos
Anticoagulantes/efeitos adversos , Citocromo P-450 CYP2C9/genética , Hispânico ou Latino/genética , Polimorfismo de Nucleotídeo Único/genética , Varfarina/efeitos adversos , Feminino , Frequência do Gene/genética , Genótipo , Humanos , Masculino , Farmacogenética/métodos , Estudos Retrospectivos
6.
Pharmacogenomics ; 20(1): 3-8, 2019 01.
Artigo em Inglês | MEDLINE | ID: mdl-30518301

RESUMO

Warfarin continues to be the mainstay therapy for preventing thrombus formation. Although pharmacogenetic algorithms have shown higher predictability of the optimal warfarin dose and lower occurrence of bleeding episodes, they often do not include ethno-specific genetic variants relevant to non-Europeans. This case report describes a rare missense variant at exon 9 of CYP2C9 (rs202201137; c.1370A>G transition; p.Asn457Ser) found in a Puerto Rican patient with low warfarin dose requirements (3 mg/day). The haplotype characterized by two amino acid changes, Asn457Ser and Arg144Cys (rs1799853; c.430C>T), has been designated CYP2C9*61 by the Pharmacogene Variation Consortium. According to prediction scores assessed with the Combined Annotation Dependent Depletion tool, CYP2C9*61 (p.Asn457Ser) was classified as nondeleterious, therefore its impact on CYP2C9 enzymatic activity cannot be postulated.


Assuntos
Anticoagulantes/administração & dosagem , Citocromo P-450 CYP2C9/genética , Hispânico ou Latino/genética , Mutação de Sentido Incorreto/genética , Varfarina/administração & dosagem , Idoso , Genótipo , Humanos , Masculino , Farmacogenética/métodos
7.
Front Pharmacol ; 8: 347, 2017.
Artigo em Inglês | MEDLINE | ID: mdl-28638342

RESUMO

Existing algorithms account for ~50% of observed variance in warfarin dose requirements after including common polymorphisms. However, they do not perform as well in populations other than Caucasians, in part because some ethno-specific genetic variants are overlooked. The objective of the present study was to identify genetic polymorphisms that can explain variability in warfarin dose requirements among Caribbean Hispanics of Puerto Rico. Next-Generation Sequencing of candidate genes CYP2C9 and VKORC1 and genotyping by DMET® Plus Assay of cardiovascular patients were performed. We also aimed at characterizing the genomic structure and admixture pattern of this study cohort. Our study used the Extreme Discordant Phenotype approach to perform a case-control association analysis. The CYP2C9 variant rs2860905, which was found in all the major haplotypes occurring in the Puerto Rican population, showed stronger association with warfarin sensitivity (<4 mg/day) than common variants CYP2C9*2 and CYP2C9*3. Although, CYP2C9*2 and CYP2C9*3 are separately contained within two of the haplotypes, 10 subjects with the sensitive phenotype were carriers of only the CYP2C9 rs2860905 variant. Other polymorphisms in CES2 and ABCB1 were found to be associated with warfarin resistance. Incorporation of rs2860905 in a regression model (R2 = 0.63, MSE = 0.37) that also includes additional genetics (i.e., VKORC1-1639 G>A; CYP2C9 rs1856908; ABCB1 c.IVS9-44A>G/ rs10276036; CES2 c.269-965A>G/ rs4783745) and non-genetic factors (i.e., hypertension, diabetes and age) showed better prediction of warfarin dose requirements than CYP2C9*2 and CYP2C9*3 combined (partial R2 = 0.132 vs. 0.023 and 0.007, respectively, p < 0.001). The genetic background of Puerto Ricans in the study cohort showed a tri-hybrid admixture pattern, with a slightly higher than expected contribution of Native American ancestry (25%). The genomic diversity of Puerto Ricans is highlighted by the presence of four different major haplotype blocks in the CYP2C9 locus. Although, our findings need further replication, this study contributes to the field by identifying novel genetic variants that increase predictability of stable warfarin dosing among Caribbean Hispanics.

8.
PLoS One ; 11(1): e0145480, 2016.
Artigo em Inglês | MEDLINE | ID: mdl-26745506

RESUMO

AIM: This study is aimed at developing a novel admixture-adjusted pharmacogenomic approach to individually refine warfarin dosing in Caribbean Hispanic patients. PATIENTS & METHODS: A multiple linear regression analysis of effective warfarin doses versus relevant genotypes, admixture, clinical and demographic factors was performed in 255 patients and further validated externally in another cohort of 55 individuals. RESULTS: The admixture-adjusted, genotype-guided warfarin dosing refinement algorithm developed in Caribbean Hispanics showed better predictability (R2 = 0.70, MAE = 0.72mg/day) than a clinical algorithm that excluded genotypes and admixture (R2 = 0.60, MAE = 0.99mg/day), and outperformed two prior pharmacogenetic algorithms in predicting effective dose in this population. For patients at the highest risk of adverse events, 45.5% of the dose predictions using the developed pharmacogenetic model resulted in ideal dose as compared with only 29% when using the clinical non-genetic algorithm (p<0.001). The admixture-driven pharmacogenetic algorithm predicted 58% of warfarin dose variance when externally validated in 55 individuals from an independent validation cohort (MAE = 0.89 mg/day, 24% mean bias). CONCLUSIONS: Results supported our rationale to incorporate individual's genotypes and unique admixture metrics into pharmacogenetic refinement models in order to increase predictability when expanding them to admixed populations like Caribbean Hispanics. TRIAL REGISTRATION: ClinicalTrials.gov NCT01318057.


Assuntos
Anticoagulantes/administração & dosagem , Fibrilação Atrial/tratamento farmacológico , Hispânico ou Latino/genética , Trombose/tratamento farmacológico , Varfarina/administração & dosagem , Adulto , Idoso , Idoso de 80 Anos ou mais , Algoritmos , Anticoagulantes/farmacocinética , Região do Caribe , Ensaios Clínicos como Assunto , Estudos de Coortes , Citocromo P-450 CYP2C9/genética , Demografia , Cálculos da Dosagem de Medicamento , Feminino , Genótipo , Meia-Vida , Humanos , Masculino , Pessoa de Meia-Idade , Polimorfismo de Nucleotídeo Único , Estudos Retrospectivos , Vitamina K Epóxido Redutases/genética , Varfarina/farmacocinética
9.
J Investig Med High Impact Case Rep ; 4(4): 2324709616682049, 2016.
Artigo em Inglês | MEDLINE | ID: mdl-28210634

RESUMO

Deep abdominal vein thrombosis is extremely rare among thrombotic events secondary to the use of contraceptives. A case to illustrate the clinical utility of ethno-specific pharmacogenetic testing in warfarin management of a Hispanic patient is reported. A 37-year-old Hispanic Puerto Rican, non-gravid female with past medical history of abnormal uterine bleeding on hormonal contraceptive therapy was evaluated for abdominal pain. Physical exam was remarkable for unspecific diffuse abdominal tenderness, and general initial laboratory results-including coagulation parameters-were unremarkable. A contrast-enhanced computed tomography showed a massive thrombosis of the main portal, splenic, and superior mesenteric veins. On admission the patient was started on oral anticoagulation therapy with warfarin at 5 mg/day and low-molecular-weight heparin. The prediction of an effective warfarin dose of 7.5 mg/day, estimated by using a recently developed pharmacogenetic-guided algorithm for Caribbean Hispanics, coincided with the actual patient's warfarin dose to reach the international normalized ratio target. We speculate that the slow rise in patient's international normalized ratio observed on the initiation of warfarin therapy, the resulting high risk for thromboembolic events, and the required warfarin dose of 7.5 mg/day are attributable in some part to the presence of the NQO1*2 (g.559C>T, p.P187S) polymorphism, which seems to be significantly associated with resistance to warfarin in Hispanics. By adding genotyping results of this novel variant, the predictive model can inform clinicians better about the optimal warfarin dose in Caribbean Hispanics. The results highlight the potential for pharmacogenetic testing of warfarin to improve patient care.

10.
Drug Metab Pers Ther ; 30(4): 239-49, 2015 Dec.
Artigo em Inglês | MEDLINE | ID: mdl-26501165

RESUMO

Puerto Ricans are a unique Hispanic population with European, Native American (Taino), and higher West African ancestral contributions than other non-Caribbean Hispanics. In admixed populations, such as Puerto Ricans, genetic variants can be found at different frequencies when compared to parental populations and uniquely combined and distributed. Therefore, in this review, we aimed to collect data from studies conducted in healthy Puerto Ricans and to report the frequencies of genetic polymorphisms with major relevance in drug response. Filtering for healthy volunteers or individuals, we performed a search of pharmacogenetic studies in academic literature databases without limiting the period of the results. The search was limited to Puerto Ricans living in the island, excluding those studies performed in mainland (United States). We found that the genetic markers impacting pharmacological therapy in the areas of cardiovascular, oncology, and neurology are the most frequently investigated. Coincidently, the top causes of mortality in the island are cardiovascular diseases, cancer, diabetes, Alzheimer's disease, and stroke. In addition, polymorphisms in genes that encode for members of the CYP450 family (CYP2C9, CYP2C19, and CYP2D6) are also available due to their relevance in the metabolism of drugs. The complex genetic background of Puerto Ricans is responsible for the divergence in the reported allele frequencies when compared to parental populations (Africans, East Asians, and Europeans). The importance of reporting the findings of pharmacogenetic studies conducted in Puerto Ricans is to identify genetic variants with potential utility among this genetically complex population and eventually move forward the adoption of personalized medicine in the island.


Assuntos
Hispânico ou Latino/genética , Polimorfismo Genético/genética , Sistema Enzimático do Citocromo P-450 , Frequência do Gene/genética , Voluntários Saudáveis , Heterozigoto , Homozigoto , Humanos , Metilenotetra-Hidrofolato Redutase (NADPH2)/genética , Mutação de Sentido Incorreto/genética , Farmacogenética , Porto Rico/etnologia , Receptores Adrenérgicos beta 2/genética , Vitamina K Epóxido Redutases/genética
11.
P R Health Sci J ; 34(1): 25-30, 2015 Mar.
Artigo em Inglês | MEDLINE | ID: mdl-25856874

RESUMO

OBJECTIVE: The objective of this study was to evaluate the cytotoxic and anticancer activities of extracts from 7-species of endemic and native plants from Puerto Rico. METHODS: The plant species selected for this study were Canella winterana, Croton discolor, Goetzea elegans, Guaiacum officinale, Pimenta racemosa, Simarouba tulae, and Thouinia striata. The dried plant material was extracted with a 1:1 mixture of CH2CI2-MeOH. The resulting crude extract was suspended in water and extracted with solvents of different polarities. The extracts were evaluated for their cytotoxic effects against Artemia salina and 3 breast cancer cell lines. RESULTS: About 50% of the extracts evaluated against Artemia salina exhibited LC50 values of less than or equal to 200 µg/mL. The strongest activity was detected in the chloroform and ethyl acetate extracts of Guaiacum officinale, with lethality values below 10 µg/mL. The extracts were further evaluated for their bioactivity as possible inhibitors of several breast cancer cell lines, with the extracts from Simarouba tulae and Croton discolor showing the highest percentages of growth inhibition. The dose- effect data analysis for the crude extracts of the different plants also confirms the high cytotoxicities of Guaiacum officinale, Simarouba tulae, and Croton discolor. CONCLUSION: Based on our results, we concluded that the Simarouba, Croton, and Guaiacum plant extracts show cytotoxic and anticancer activities that merit closer investigation in order to identify the chemical compounds responsible for these bioactivities.


Assuntos
Antineoplásicos Fitogênicos/farmacologia , Neoplasias da Mama/tratamento farmacológico , Extratos Vegetais/farmacologia , Plantas Medicinais/química , Animais , Antineoplásicos Fitogênicos/administração & dosagem , Antineoplásicos Fitogênicos/toxicidade , Artemia , Neoplasias da Mama/patologia , Relação Dose-Resposta a Droga , Feminino , Humanos , Dose Letal Mediana , Extratos Vegetais/administração & dosagem , Extratos Vegetais/toxicidade , Porto Rico , Solventes/química
12.
Drug Metab Pers Ther ; 30(2): 87-105, 2015 Jun.
Artigo em Inglês | MEDLINE | ID: mdl-25431893

RESUMO

Although the Hispanic population is continuously growing in the United States, they are underrepresented in pharmacogenetic studies. This review addresses the need for compiling available pharmacogenetic data in US Hispanics, discussing the prevalence of clinically relevant polymorphisms in pharmacogenes encoding for drug-metabolizing enzymes. CYP3A5*3 (0.245-0.867) showed the largest frequency in a US Hispanic population. A higher prevalence of CYP2C9*3, CYP2C19*4, and UGT2B7 IVS1+985 A>G was observed in US Hispanic vs. non-Hispanic populations. We found interethnic and intraethnic variability in frequencies of genetic polymorphisms for metabolizing enzymes, which highlights the need to define the ancestries of participants in pharmacogenetic studies. New approaches should be integrated in experimental designs to gain knowledge about the clinical relevance of the unique combination of genetic variants occurring in this admixed population. Ethnic subgroups in the US Hispanic population may harbor variants that might be part of multiple causative loci or in linkage-disequilibrium with functional variants. Pharmacogenetic studies in Hispanics should not be limited to ascertain commonly studied polymorphisms that were originally identified in their parental populations. The success of the Personalized Medicine paradigm will depend on recognizing genetic diversity between and within US Hispanics and the uniqueness of their genetic backgrounds.


Assuntos
Sistema Enzimático do Citocromo P-450/genética , Hispânico ou Latino/genética , Preparações Farmacêuticas/metabolismo , Alelos , Sistema Enzimático do Citocromo P-450/metabolismo , Genótipo , Glucuronosiltransferase/genética , Glucuronosiltransferase/metabolismo , Glutationa Transferase/genética , Glutationa Transferase/metabolismo , Humanos , Acetiltransferases N-Terminal/genética , Acetiltransferases N-Terminal/metabolismo , Prevalência , Estados Unidos
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA
...